ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
9 announcements with these filters
Jenburkt Pharmaceuticals clarified its shares are permitted to trade on NSE without a listing application. The shares remain listed on BSE under the Permitted to Trade category.
Mr. Vinay Bhatt, Senior Vice President- International Business, has resigned from Jenburkt Pharmaceuticals Limited effective September 18, 2026, due to personal reasons.
Jenburkt Pharmaceuticals held its 41st Annual General Meeting on 4th September, 2026, to discuss financial statements, dividend declaration, and director appointments.
Jenburkt Pharmaceuticals elevated Shri Prem Ashish Bhuta to Associate Vice President – Strategic Initiatives. He is now classified as Senior Management Personnel effective September 4, 2026.
Jenburkt Pharmaceuticals Ltd reported revenue from operations of ₹35.5 Cr (+0.0% YoY) and net profit of ₹5.9 Cr (-24.4% YoY) for Q1 FY27.
Jenburkt Pharmaceuticals Limited has scheduled its 41st Annual General Meeting for September 4, 2026, through video conferencing. Shareholders will vote on financial adoption, dividend declaration, and director appointments.
Jenburkt Pharmaceuticals Ltd reported revenue from operations of ₹168.7 Cr (+11.2% YoY) and net profit of ₹34.7 Cr (+8.1% YoY) for Q4 FY26.
Jenburkt Pharmaceuticals scheduled a board meeting for August 6, 2026, to consider the company's standalone unaudited financial results for the quarter ended June 30, 2026.
Jenburkt Pharmaceuticals approved shifting its registered office within Mumbai effective July 21, 2026. Contact details and ROC jurisdiction remain unchanged.